Altamira Medica AG · Basel, Switzerland
A Swiss medical device company on a mission to protect millions of people from airborne allergens — through ®, a drug-free nasal spray developed in Switzerland.
Our principles
Altamira Medica is headquartered in Basel — Switzerland's life sciences capital — with a European presence in Dublin, Ireland.
We commercialise ®, a nasal spray formulated with natural Bentonite that protects without drugs, preservatives or pharmacological side effects.
® is certified under EU MDR (EU 2017/745, CE 2797). Clinically tested, well-tolerated, and built on ingredients with established safety profiles.
The need
Allergic rhinitis affects 10–30% of adults and up to 40% of children. The next answer should not always be a drug.
Sources: World Allergy Organization, White Book on Allergy (Update 2013). European Academy of Allergy and Clinical Immunology (EAACI).
The opportunity
Source: Euromonitor International, Cough, Cold and Allergy Remedies in World, Datagraphics, March 2026; Euromonitor International, Global Allergy Market Datagraphics, 2026.
Drug-freeThe product — ®
® is a Swiss-developed nasal spray that forms a protective gel barrier on the nasal lining — clinically proven to shield against pollen and dust mites in seconds.
Trusted by professional athletes
Tested for drugs and banned substances — chosen by competitive athletes who need clear airways without compromising clean-sport rules.
Quality & Compliance
® undergoes rigorous testing and is built on ingredients with well-established safety profiles. It has no pharmacological, immunologic, or metabolic effects — and it is well tolerated in clinical use.
Philip Winzeler
Chief Executive Officer, Altamira Medica
A word from the CEO
With our nasal spray ®, we developed a comprehensive nasal protection platform based on a purely physical, drug-free mode of action. In a first step, we demonstrated ®'s efficacy in allergic rhinitis. Ultimately, we aim to position it as the product of choice for protection against harmful inhaled particles.
◆ Now seeking national partners
Partnering
Altamira Medica is actively expanding the global footprint of ® through long-term partnerships through national distributors and licensees in consumer health. We offer a regulatory-cleared, clinically validated and patent-protected medical device — supported by a sustainable European supply chain.
Regulatory Status
Robust clinical data supports efficacy in allergic rhinitis
Quality management system ISO 13485 and MDR certified.
Patent protected.
® Market Availability
Active commercial partnerships in Europe and Asia. Significant geographies remain available for new partners.
What Altamira Offers
Cleared in key markets
Altamira Medica holds US FDA 510(k) clearance, EU Class IIa under MDR, and NMPA approval in China.
Validated clinical data
Strong evidence demonstrating ®'s efficacy in allergic rhinitis.
Patent protected
Patents granted in key markets, with further countries pending.
Sustainable partnerships
Current partners are successfully expanding their footprint with incremental country coverage.
Market exclusivity
Country-level exclusivity available for committed national partners.
What We Seek
National distributors & licensees
Established healthcare and consumer-health players with proven retail and pharmacy reach.
Strong commercial commitment
Partners willing to invest in market development.
Regulatory & quality capability
Local registration, vigilance and quality management systems aligned with applicable regulatory requirements.
Aligned values
Long-term, transparent, science-driven collaboration.
Why ®?
Drug-free protection
Forms a protective gel barrier in the nasal cavity that traps and helps remove allergens - without steroids or antihistamines.
Differentiated category
A unique mechanical mode of action that complements existing allergy portfolios rather than cannibalising them.
Global momentum
Successfully launched in Europe and Asia - with significant whitespace remaining.
Proven supply chain
Manufactured in Germany by NextPharma, a leading European pharmaceutical contract manufacturer.
05 — Featured Partners
® reaches sufferers through a select network of regional specialists. Two flagship partnerships anchor our presence across Asia Pacific and the Nordic region.
China, Hong Kong, Macau and South Korea
Specialty care biopharma — respiratory leadership in Asia
Founded in 2014, Nuance Pharma is a Shanghai-headquartered specialty biopharmaceutical company committed to bringing transformational therapies to sufferers in China and Asia. Nuance licensed ® from Altamira and launched it in Hong Kong in 2022, with ongoing expansion across the region.
Visit Nuance PharmaNordic Region
Innovative self-care for the Nordic region
Pharma Nordic is a physician-led pharmaceutical company on a mission to be the Nordic leader in self-care. They hold licenses and distribution rights for innovative pharmaceuticals and medical devices across the Nordics — started bringing ® to sufferers since 2023 in Norway, expanding to Sweden and Denmark, with further Nordic markets on the roadmap.
Visit Pharma NordicPartner names and references are used solely to describe the scope of commercial collaboration. Logos and trademarks of partner organisations are used with consent or in editorial reference.
03 — Research & Regulatory
Altamira Medica collaborates with leading academic and clinical institutions across Europe, North America and Asia. The references below describe the role of each partner. They do not constitute product endorsement.
Allergen Challenge Chamber
® was evaluated in a controlled grass pollen exposure study conducted in the Fraunhofer ITEM Allergen Challenge Chamber.
Clinical Trial Conduct
Controlled allergen exposure work for the house dust mite study was conducted with Cliantha Research (formerly Inflamax Research).
Clinical Trial Management
Novotech, a leading Asia-Pacific contract research organisation, managed the NASAR real-life clinical study of ® in seasonal allergic rhinitis across Australian sites.
Current Manufacturing Partner
® is manufactured by NextPharma in Waltrop, Germany, a leading pharmaceutical manufacturer committed to quality and innovation.
Institutional names are used solely to describe the scope of collaboration.
The team
Lean by design and global in reach. Supported by external specialists in clinical, manufacturing and finance across markets.
Chief Executive Officer
Leads Altamira's vision and international expansion, aligning strategy, operations and capital so the company can scale Bentrio responsibly across new markets.
Chief Operating Officer
First point of contact for distribution partners, guiding partner-led launch planning, alliance management and all things marketing.
Chief Quality & Regulatory Officer (PRRC)
Drives Bentrio's quality management system and global regulatory strategy while safeguarding product safety, compliance and the standards allergy sufferers rely on.
Headquartered in Basel
Switzerland
01Ireland
02Australia
03
